GE Healthcare, Eli Lilly, ABI, Olink Bioscience, Perlegen, 454, Invitrogen, Natural Selection, Bio-Rad, DiaMed, Celera, Siemens, Salk Institute, Univ. of Marburg, Abbott, Epigenomics, SeqWright | GenomeWeb
GE Healthcare, Lilly to Develop IVDs for Cancer Therapy Prediction
 
Eli Lilly has signed a three-year collaboration with GE Healthcare and GE Global Research to develop in vitro diagnostics to predict the response of patients to targeted cancer therapies, the companies said this week.
 
The collaboration covers targeted cancer therapeutics under development at Lilly and GE’s multiplexed tissue-based assays and image analysis tools.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.